PRINCETON, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and…
PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3 TRIAL IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER, WITH BIOMARKER-DRIVEN…
SINGAPORE, July 3, 2025 /PRNewswire/ -- Azentio Software ("Azentio"), a leading technology enabler in the banking, financial services, insurance (BFSI),…
July 02, 2025 03:00 ET | Source: Belite Bio, Inc - 500 subjects enrolled across the United States, the United…
July 01, 2025 09:00 ET | Source: Inmagene Biopharmaceuticals The ADAPTIVE Phase 2b trial evaluates multiple dose regimens of IMG-007…
New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for…
Phase 2 highlights robust biomarker identification and survival correlations in first-line metastatic pancreatic cancer (mPDAC) treated with elraglusib June 20,…
Larry Cermak transitions to President role to focus on research and product innovation; Kaleb Jessee promoted to CEO NEW YORK,…
June 16, 2025 19:20 ET | Source: PolyPid Ltd. The Company Anticipates that with this Additional Funding, PolyPid’s Runway would…
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage…